2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

Supported through funding from

Dual immunotherapy for cancer has been one of the most successful modes of treatment researched and developed in recent years, with many new studies having been completed this past year. Immunotherapy has been used in the past for oncological treatments with monotherapy and in combination with chemotherapy; these new studies provide data on the success of combinations of various monoclonal antibodies for treatment of solid tumors.

These major research advances have been compiled from presentations at the 2021 American Society of Clinical Oncology and 2021 European Society for Medical Oncology annual meetings, in addition to manuscripts published in key journals. This year in review summarizes data on these important and innovative therapies.